What began as a search for hormone-processing enzymes ultimately transformed the treatment of high cholesterol.

Adults with a history of or at risk for a first atherosclerotic cardiovascular disease (ASCVD) event who received the oral proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor enlicitide ...

Cardiovascular disease (CVD) remains the leading cause of death globally. Hypercholesterolemia is a major modifiable risk factor for developing atherosclerotic CVD (ASCVD). Although statins are the ...

An experimental pill called enlicitide was found to dramatically lower LDL (“bad”) cholesterol by ~60% in a large phase 3 clinical trial. The study ...

A once-a-day tablet called enlicitide is reshaping expectations for cholesterol care, cutting low density lipoprotein, or ...

BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing ...

Richa Munjal considers the current landscape for PCSK9 inhibitors and whether there is a brighter future on the horizon for this class of drugs. The promise of a new era of cholesterol management, ...

A new study published in The New England Journal of Medicine showed that at 24 weeks, therapy with the oral PCSK9 inhibitor ...

Although some of the barriers that have kept cholesterol-lowering PCSK9 inhibitors out of reach for many patients in the United States have eased a bit in recent years, a new analysis suggests that ...

In business parlance, a bolt-on acquisition is one in which the smaller company offers its acquirer strategic value. Swiss drugmaker Novartis’ recently announced $9.7 billion takeover of The Medicines ...

Please provide your email address to receive an email when new articles are posted on . Proprotein convertase subtilisin/kexin type 9, also known as PCSK9, provides instructions for the body to ...

New York, USA, Feb. 17, 2025 (GLOBE NEWSWIRE) -- PCSK9 Inhibitors Market Anticipate to Accelerate in the Coming 10 Years Owing to the Increasing Demand for Innovative Cholesterol-Lowering Drugs | ...